Technical Analysis for SGEN - Seattle Genetics, Inc.
|Grade||Last Price||% Change||Price Change|
SGEN closed down 0.61 percent on Thursday, February 22, 2018, on 73 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
|Weak or Absent||Down||Flat||Up|
|See historical SGEN trend table...|
|Date||Alert Name||Type||% Chg|
|Feb 22||Fell Below 50 DMA||Bearish||0.00%|
|Feb 21||50 DMA Support||Bullish||-0.61%|
|Feb 21||NR7||Range Contraction||-0.61%|
|Feb 21||Inside Day||Range Contraction||-0.61%|
|Feb 21||Wide Bands||Range Expansion||-0.61%|
|Feb 20||50 DMA Support||Bullish||-0.70%|
|Feb 20||Wide Bands||Range Expansion||-0.70%|
|Feb 16||Doji - Bearish?||Reversal||-2.09%|
|Feb 16||Wide Bands||Range Expansion||-2.09%|
|Feb 16||Up 3 Days in a Row||Strength||-2.09%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS, has accelerated approval form the U.S. Food and Drug Administration for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens; and for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. The company's ADCETRIS is in Phase III trial for patients with Hodgkin lymphoma at high risk of relapse following ASCT; Phase II retreatment trial for patients with Hodgkin lymphoma or sALCL; Phase II trial for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas; Phase II CD30-screening and treatment trial for patients with CD30-positive non-lymphoma malignancies; Phase I safety trial in combination with Adriamycin, vinblastine, bleomycin, and dacarbazine, or in combination with AVD for front-line treatment of patients with Hodgkin lymphoma; and Phase I safety trial for the treatment of patients with mature T-cell lymphomas, including sALCL. Its product pipeline also comprises SGN-75, which completed Phase I trial for relapsed or refractory non-Hodgkin lymphoma and renal cell carcinoma; ASG-5ME that is in Phase I trial for treating metastatic pancreatic cancer and castration-resistant prostate cancer; ASG-22ME, which is in Phase I trial for treatment of Nectin-4 -positive solid tumors; and SGN-CD19A for CD19-positive hematologic malignancies. The company has a strategic collaboration with Oxford BioTherapeutics Ltd. to jointly discover antibody-drug conjugates (ADC) for the treatment of cancer. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more SGEN news...
|52 Week High||71.32|
|52 Week Low||45.31|
|200-Day Moving Average||56.1857|
|50-Day Moving Average||53.9859|
|20-Day Moving Average||53.926|
|10-Day Moving Average||53.103|
|Average True Range||2.0465|
|Chandelier Exit (Long, 3 ATRs )||51.7705|
|Chandelier Exit (Short, 3 ATRs )||54.9195|
|Upper Bollinger Band||57.5847|
|Lower Bollinger Band||50.2673|
|Percent B (%b)||0.48|
|MACD Signal Line||-0.3442|
|Market Cap||7.69 Billion|
|Num Shares||143 Million|
|Price-to-Earnings (P/E) Ratio||-37.61|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||56.12|
|Resistance 3 (R3)||56.30||55.70||55.73|
|Resistance 2 (R2)||55.70||55.10||55.61||55.60|
|Resistance 1 (R1)||54.74||54.74||54.44||54.56||55.47|
|Support 1 (S1)||53.18||53.54||52.88||53.00||52.09|
|Support 2 (S2)||52.58||53.18||52.49||51.96|
|Support 3 (S3)||51.62||52.58||51.83|
|Support 4 (S4)||51.44|